Literature DB >> 15920645

Glucose and insulin influences on heart and brain in cardiac surgery.

David W Quinn1, Domenico Pagano, Robert S Bonser.   

Abstract

The elective global ischemia of on-pump coronary artery bypass surgery contributes to the incidence of postoperative mortality, complications, and use of resources. In addition to cardiopulmonary bypass and techniques for myocardial protection such as aortic cross clamp, ventricular fibrillation, and cardioplegia, the administration of systemic glucose-insulin-potassium (GIK) in the perioperative period may act as both a metabolic modulator and potential inodilator. GIK may therefore serve to protect the myocardium and promote adequate cardiac and hemodynamic performance that would improve patient recovery. Cell, tissue, and animal experiments have determined a number of mechanisms of action by which this may be achieved, with increasing focus on insulin as the key component. The original concepts centered on GIK during or after ischemia switching metabolism away from that based on non-esterified fatty acids toward a more favorable glucose-based metabolism and thus improving the efficiency of adenosine triphosphate production and glycogen preservation. Insulin's ability to reduce intracellular fatty acid metabolism may also reduce cellular membrane damage. More recently other mechanisms have also been suggested, including osmotic, oxygen free radical scavenging, and antiapoptotic and anti-inflammatory effects. However, trials that have examined the role of GIK in cardiac surgery have been small, open label, and involved a wide variety of regimens. They have demonstrated improved glycogen preservation, reduced infarct size, reduced incidences of dysrhythmias, need for inotropic agents, and low cardiac output state, and overall reduced lengths of stay. The perceived need to achieve strict blood glucose control to reduce neurologic injury and improve overall mortality have conflicted with its practical difficulties, particularly during cold cardiopulmonary bypass, and the exact role of supplemental glucose administration and resulting hyperglycemia require re-examination.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15920645     DOI: 10.1177/108925320500900213

Source DB:  PubMed          Journal:  Semin Cardiothorac Vasc Anesth        ISSN: 1089-2532


  4 in total

Review 1.  Hyperglycemia as an effect of cardiopulmonary bypass: intra-operative glucose management.

Authors:  Samira Najmaii; Daniel Redford; Douglas F Larson
Journal:  J Extra Corpor Technol       Date:  2006-06

2.  Postoperative atrial fibrillation.

Authors:  C Chelazzi; G Villa; A R De Gaudio
Journal:  ISRN Cardiol       Date:  2011-05-22

3.  Non-invasive evaluation of new-onset atrial fibrillation after cardiac surgery: a protocol for the BigMap study.

Authors:  Constantin Mork; Simon Adrian Amacher; Brigitta Gahl; Luca Koechlin; Jules Miazza; Thibault Schaeffer; Lena Schmuelling; Jens Bremerich; Denis Berdajs; Nadine Cueni; Michael Kühne; Christian Mueller; Stefan Osswald; Oliver Reuthebuch; Ulrich Schurr; Christian Sticherling; Andrea Kopp Lugli; Stephan Marsch; Hans Pargger; Martin Siegemund; Friedrich Eckstein; Alexa Hollinger; David Santer
Journal:  ESC Heart Fail       Date:  2022-04-19

4.  Change in the perioperative blood glucose and blood lactate levels of non-diabetic patients undergoing coronary bypass surgery.

Authors:  Chunjian Shen; Tianxiang Gu; Lili Gu; Zhongyi Xiu; Zhiwei Zhang; Enyi Shi; Yuhai Zhang; Chun Wang
Journal:  Exp Ther Med       Date:  2013-08-22       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.